Literature DB >> 20492336

Correlations among Helicobacter pylori infection and the expression of cyclooxygenase-2 and vascular endothelial growth factor in gastric mucosa with intestinal metaplasia or dysplasia.

Dongping Liu1, Qingjuan He, Caigang Liu.   

Abstract

BACKGROUND AND AIMS: To examine the rate of Helicobacter pylori infection and the expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in gastric mucosa with intestinal metaplasia or dysplasia, and explore their correlations in precancerous gastric lesions.
METHODS: A total of 172 patients were included in the study. H. pylori infection was evaluated by hematoxylin-eosin and modified Giemsa staining. The expression of COX-2 and VEGF proteins was detected by immunohistochemistry.
RESULTS: The rates of H. pylori infection in gastric mucosal dysplasia (DYS), intestinal metaplasia in gastric mucosa (IM), chronic atrophic gastritis (CAG) and chronic superficial gastritis (CSG) patients were significant differences (P = 0.001). The average optical density (AOD) values of COX-2 staining in CSG, CAG, IM and DYS patients were 13.81 +/- 5.53, 45.28 +/- 21.44, 73.67 +/- 26.02 and 91.23 +/- 45.11, respectively, with significant differences among CSG, CAG and IM patients (P = 0.037, 0.001 and 0.047 for CSG vs CAG, CSG vs IM and CAG vs IM, respectively). The expression level of VEGF in DYS patients was significantly higher than those in other patients (P = 0.001, 0.001 and 0.001 for DYS vs CSG, DYS vs CAG and DYS vs IM, respectively). The expression levels of COX-2 in H. pylori-positive IM, CAG and DYS patients were significantly higher than those in H. pylori-negative counterparts (P = 0.043, 0.009, 0.001, respectively). Additionally, the expression level of COX-2 was positively correlated with that of VEGF with the aggravation of gastric mucosal lesions (r = 0.640, P = 0.006).
CONCLUSION: H. pylori infection might be able to induce the expression of COX-2 in precancerous gastric lesions, which in turn upregulates the expression of VEGF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20492336     DOI: 10.1111/j.1440-1746.2009.06168.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  11 in total

Review 1.  Helicobacter pylori infection, gastrin and cyclooxygenase-2 in gastric carcinogenesis.

Authors:  Yun Shao; Kun Sun; Wei Xu; Xiao-Lin Li; Hong Shen; Wei-Hao Sun
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

2.  VEGF-A and VEGF-B mRNA expression in gastro-oesophageal cancers.

Authors:  Cristina Angelescu; Florin Burada; Mihai Ioana; Radu Angelescu; Emil Moraru; Anca Riza; Sanda Marchian; Francisc Mixich; Mihai Cruce; Adrian Săftoiu
Journal:  Clin Transl Oncol       Date:  2012-08-08       Impact factor: 3.405

3.  Oesophageal squamous cell carcinoma in high-risk Chinese populations: Possible role for vascular epithelial growth factor A.

Authors:  Asieh Golozar; Terri H Beaty; Patti E Gravitt; Ingo Ruczinski; You-Lin Qiao; Jin-Hu Fan; Ti Ding; Ze-Zhong Tang; Arash Etemadi; Nan Hu; Paula L Hyland; Lemin Wang; Chaoyu Wang; Sanford M Dawsey; Neal D Freedman; Christian C Abnet; Alisa M Goldstein; Philip R Taylor
Journal:  Eur J Cancer       Date:  2014-08-26       Impact factor: 9.162

4.  Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer.

Authors:  Zhu Li; Xu Hou; Juan Chen; Huidong Sun; Yuetang Mi; Yongling Sui; Yuhong Li; Jiaping Xie; Yingli Qiao; Xiaofeng Lei; Xiaoshuang Che; Jun Liu
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

5.  Adiponectin deficiency contributes to the development and progression of benign prostatic hyperplasia in obesity.

Authors:  Shi Fu; Huan Xu; Meng Gu; Chong Liu; Qiong Wang; Xiang Wan; Yanbo Chen; Qi Chen; Yubing Peng; Zhikang Cai; Juan Zhou; Zhong Wang
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

6.  Exploring the potential pharmacodynamic material basis and pharmacologic mechanism of the Fufang-Xialian-Capsule in chronic atrophic gastritis by network pharmacology approach based on the components absorbed into the blood.

Authors:  Shizhe Li; Tengfei Xu; Shu Liu; Zhiqiang Liu; Zifeng Pi; Fenrui Song; Yongri Jin
Journal:  R Soc Open Sci       Date:  2018-06-13       Impact factor: 2.963

7.  Weiqi Decoction Attenuated Chronic Atrophic Gastritis with Precancerous Lesion through Regulating Microcirculation Disturbance and HIF-1α Signaling Pathway.

Authors:  Jing Yin; Jinyu Yi; Chun Yang; Bo Xu; Jiang Lin; Hongyi Hu; Xiaojun Wu; Hailian Shi; Xiaoyan Fei
Journal:  Evid Based Complement Alternat Med       Date:  2019-06-20       Impact factor: 2.629

8.  Chronic atrophic gastritis and intestinal metaplasia induced by high-salt and N-methyl-N'-nitro-N-nitrosoguanidine intake in rats.

Authors:  Jing Yin; Jinyu Yi; Chun Yang; Bo Xu; Jiang Lin; Hongyi Hu; Xiaojun Wu; Hailian Shi; Xiaoyan Fei
Journal:  Exp Ther Med       Date:  2021-02-03       Impact factor: 2.447

9.  In vitro anti-bacterial activity and network pharmacology analysis of Sanguisorba officinalis L. against Helicobacter pylori infection.

Authors:  Xue Shen; Weijia Zhang; Chang Peng; Jiahui Yan; Pengting Chen; Cheng Jiang; Yuemei Yuan; Donglian Chen; Weixing Zhu; Meicun Yao
Journal:  Chin Med       Date:  2021-04-17       Impact factor: 5.455

10.  Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis.

Authors:  Chao Lu; Jianzhong Sang; Haijian He; Xingyong Wan; Yiming Lin; Lan Li; Youming Li; Chaohui Yu
Journal:  Sci Rep       Date:  2016-03-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.